Bhalla R C, Sharma R V
J Cardiovasc Pharmacol. 1986 Sep-Oct;8(5):927-32. doi: 10.1097/00005344-198609000-00007.
We have characterized [3H]prazosin binding to purified plasma membranes isolated from bovine carotid arteries and studied the effects of Na+ and Ca2+ channel blockers on [3H]prazosin binding to alpha 1-adrenoceptors. Amiloride and verapamil competitively inhibited the specific binding of [3H]prazosin to purified plasma membranes isolated from bovine carotid artery in a dose-dependent manner. The Ki values of verapamil and amiloride for alpha 1-adrenergic receptor were 1.04 +/- 0.037 microM and 32.6 +/- 0.59 microM, respectively. Verapamil (10 microM) and amiloride (100 microM) caused a 6-fold and 2.7-fold decrease in affinity of [3H]prazosin binding, respectively, with no change in the number of binding sites. The inhibition of [3H]prazosin binding by amiloride and verapamil could be reversed after the membranes were washed. Another Ca2+-channel blocker, nifedipine, and a Na+-channel blocker, furosemide, did not significantly inhibit [3H]prazosin binding up to 0.1 mM concentrations. Our results suggest that amiloride and verapamil may produce vascular smooth muscle relaxation by modulating alpha 1-adrenoceptor affinity in addition to blocking Na+ and Ca2+ channels, respectively.
我们已对从牛颈动脉分离出的纯化质膜上的[³H]哌唑嗪结合进行了表征,并研究了Na⁺和Ca²⁺通道阻滞剂对[³H]哌唑嗪与α1-肾上腺素能受体结合的影响。氨氯吡咪和维拉帕米以剂量依赖性方式竞争性抑制[³H]哌唑嗪与从牛颈动脉分离出的纯化质膜的特异性结合。维拉帕米和氨氯吡咪对α1-肾上腺素能受体的Ki值分别为1.04±0.037微摩尔和32.6±0.59微摩尔。维拉帕米(10微摩尔)和氨氯吡咪(100微摩尔)分别使[³H]哌唑嗪结合的亲和力降低6倍和2.7倍,而结合位点数量无变化。洗涤质膜后,氨氯吡咪和维拉帕米对[³H]哌唑嗪结合的抑制作用可被逆转。另一种Ca²⁺通道阻滞剂硝苯地平和一种Na⁺通道阻滞剂呋塞米在浓度高达0.1毫摩尔时,对[³H]哌唑嗪结合无明显抑制作用。我们的结果表明,氨氯吡咪和维拉帕米除了分别阻断Na⁺和Ca²⁺通道外,还可能通过调节α1-肾上腺素能受体亲和力来产生血管平滑肌舒张作用。